Nevirapine (Viramune): European Warning

On April 12 the European Agency for the Evaluation of Medicinal Products (EMEA) issued a warning on risks of severe or life-threatening skin or liver reactions to nevirapine, requiring precautions especially for patients starting the drug, during their first 8 weeks of treatment. The full public statement is available at: http://www.emea.eu.int/

In the U.S., some but not all of this information is already in the drug labeling, and new data from clinical trials is being analyzed to fine-tune any additional warnings required.